NEC Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about NEC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 717 trials

Recruiting
Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled192 locationsNCT06568172
Recruiting

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Disorders of Sex Development (DSD)Pediatric and Adolescent Cancers of the Genital TractReproductive Endocrine Conditions in Puberty+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)11,000 enrolled1 locationNCT04717349
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 2

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled18 locationsNCT07195734
Recruiting
Phase 2

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled170 locationsNCT04671667
Recruiting
Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled175 locationsNCT06589804
Recruiting
Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled3 locationsNCT06980038
Recruiting
Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting
Phase 1

Study of CHS-114 in Participants With Advanced Solid Tumors

Advanced Solid TumorHead and Neck Squamous Cell Carcinoma
Coherus Oncology, Inc.87 enrolled16 locationsNCT05635643
Recruiting
Not Applicable

Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer

Head and Neck CancerUpper Aerodigestive Tract Cancer
Centre Hospitalier de Valence96 enrolled1 locationNCT06184880
Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 2

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Wake Forest University Health Sciences38 enrolled1 locationNCT04375384
Recruiting
Phase 1

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Head and Neck Squamous Cell Carcinoma
Boehringer Ingelheim90 enrolled57 locationsNCT06806852
Recruiting
Phase 3

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Head and Neck Squamous Cell Carcinoma
Merus B.V.500 enrolled207 locationsNCT06496178
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled154 locationsNCT04389632
Recruiting

Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders

Pulmonary HypertensionConnective Tissue DiseaseAdult Congenital Heart Disease+1 more
Children's Hospital Medical Center, Cincinnati5,000 enrolled1 locationNCT07477197
Recruiting
Phase 3

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Locally Advanced Head and Neck Squamous Cell CarcinomaAged
Johnson & Johnson Enterprise Innovation Inc.500 enrolled189 locationsNCT04892173